These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

701 related items for PubMed ID: 15363980

  • 1. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
    Yoburn BC, Purohit V, Patel K, Zhang Q.
    Eur J Pharmacol; 2004 Sep 13; 498(1-3):87-96. PubMed ID: 15363980
    [Abstract] [Full Text] [Related]

  • 2. Continuous opioid agonist treatment dose-dependently regulates mu-opioid receptors and dynamin-2 in mouse spinal cord.
    Zhang Q, Purohit V, Yoburn BC.
    Synapse; 2005 Jun 01; 56(3):123-8. PubMed ID: 15765525
    [Abstract] [Full Text] [Related]

  • 3. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
    Pawar M, Kumar P, Sunkaraneni S, Sirohi S, Walker EA, Yoburn BC.
    Eur J Pharmacol; 2007 Jun 01; 563(1-3):92-101. PubMed ID: 17349996
    [Abstract] [Full Text] [Related]

  • 4. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo.
    Yoburn BC, Gomes BA, Rajashekara V, Patel C, Patel M.
    Synapse; 2003 Feb 01; 47(2):109-16. PubMed ID: 12454948
    [Abstract] [Full Text] [Related]

  • 5. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.
    Shen J, Benedict Gomes A, Gallagher A, Stafford K, Yoburn BC.
    Synapse; 2000 Dec 01; 38(3):322-7. PubMed ID: 11020235
    [Abstract] [Full Text] [Related]

  • 6. In vivo regulation of mu-opioid receptor density and gene expression in CXBK and outbred Swiss Webster mice.
    Duttaroy A, Yoburn BC.
    Synapse; 2000 Aug 01; 37(2):118-24. PubMed ID: 10881033
    [Abstract] [Full Text] [Related]

  • 7. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
    Sterious SN, Walker EA.
    J Pharmacol Exp Ther; 2003 Jan 01; 304(1):301-9. PubMed ID: 12490605
    [Abstract] [Full Text] [Related]

  • 8. mu-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to mu-opioid receptor agonists: Comparison between etorphine and morphine.
    Narita M, Suzuki M, Narita M, Niikura K, Nakamura A, Miyatake M, Yajima Y, Suzuki T.
    Neuroscience; 2006 Jan 01; 138(2):609-19. PubMed ID: 16417975
    [Abstract] [Full Text] [Related]

  • 9. Opioid receptor regulation in mice.
    Yoburn BC, Billings B, Duttaroy A.
    J Pharmacol Exp Ther; 1993 Apr 01; 265(1):314-20. PubMed ID: 8386239
    [Abstract] [Full Text] [Related]

  • 10. Chronic opioid antagonist treatment selectively regulates trafficking and signaling proteins in mouse spinal cord.
    Patel CN, Rajashekara V, Patel K, Purohit V, Yoburn BC.
    Synapse; 2003 Oct 01; 50(1):67-76. PubMed ID: 12872295
    [Abstract] [Full Text] [Related]

  • 11. Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo.
    Patel MB, Patel CN, Rajashekara V, Yoburn BC.
    Mol Pharmacol; 2002 Dec 01; 62(6):1464-70. PubMed ID: 12435815
    [Abstract] [Full Text] [Related]

  • 12. [(35)S]GTPγS binding and opioid tolerance and efficacy in mouse spinal cord.
    Madia PA, Navani DM, Yoburn BC.
    Pharmacol Biochem Behav; 2012 Mar 01; 101(1):155-65. PubMed ID: 22108651
    [Abstract] [Full Text] [Related]

  • 13. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
    Zernig G, Burke T, Lewis JW, Woods JH.
    J Pharmacol Exp Ther; 1996 Oct 01; 279(1):23-31. PubMed ID: 8858971
    [Abstract] [Full Text] [Related]

  • 14. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
    Liu-Chen LY, Yang HH, Li S, Adams JU.
    J Pharmacol Exp Ther; 1995 Jun 01; 273(3):1047-56. PubMed ID: 7791074
    [Abstract] [Full Text] [Related]

  • 15. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
    Zhao GM, Qian X, Schiller PW, Szeto HH.
    J Pharmacol Exp Ther; 2003 Dec 01; 307(3):947-54. PubMed ID: 14534366
    [Abstract] [Full Text] [Related]

  • 16. Agonist-specific down regulation of mu-opioid receptors: Different cellular pathways are activated by different opioid agonists.
    Binyaminy B, Gafni M, Shapira M, Sarne Y.
    Life Sci; 2008 Apr 09; 82(15-16):831-9. PubMed ID: 18358497
    [Abstract] [Full Text] [Related]

  • 17. Continuous intrathecal opioid treatment abolishes the regulatory effects of magnesium and guanine nucleotides on mu opioid receptor binding in rat spinal membranes.
    Wong CS, Su YF, Watkins WD, Chang KJ.
    J Pharmacol Exp Ther; 1992 Jul 09; 262(1):317-26. PubMed ID: 1320689
    [Abstract] [Full Text] [Related]

  • 18. Differential regulation of mu and delta opiate receptors by morphine, selective agonists and antagonists and differentiating agents in SH-SY5Y human neuroblastoma cells.
    Zadina JE, Harrison LM, Ge LJ, Kastin AJ, Chang SL.
    J Pharmacol Exp Ther; 1994 Sep 09; 270(3):1086-96. PubMed ID: 7932156
    [Abstract] [Full Text] [Related]

  • 19. Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats by reversing the coupling of mu-opioid receptors from Gs-protein to coupling to Gi-protein.
    Tsai RY, Tai YH, Tzeng JI, Cherng CH, Yeh CC, Wong CS.
    Neuroscience; 2009 Dec 01; 164(2):435-43. PubMed ID: 19682558
    [Abstract] [Full Text] [Related]

  • 20. Functional reduction in mu-opioidergic system in the spinal cord under a neuropathic pain-like state following chronic ethanol consumption in the rat.
    Narita M, Miyoshi K, Narita M, Suzuki T.
    Neuroscience; 2007 Feb 09; 144(3):777-82. PubMed ID: 17156932
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.